Lercanidipine in ethanol-0.04M Britton-Robinson buffer (20 + 80) gives an irreversible anodic response on a glassy carbon electrode in a broad pH range (2-12) that depends on pH. This signal can be attributed to oxidation ...

An HPLC reversed phase method using both UV (356 nm) and electrochemical (1000 mV) detection was developed in order to determine lercanidipine in commercial tablets. Repeatability and reproducibility were adequate. For ...

Lercanidipine is a new third generation 1,4-dihydropyridine calcium antagonist derivative used in hypertension treatments. From the structural point of view lercanidipine contains a nitroaromatic moiety which can be ...

Lercanidipine (LERCA) is a third generation antihypertensive drug belonging to the 1,4-dihydropyridine's family, which has been reported to induce photoallergic and/or phototoxic effects in patients with long term treatment. ...

Hypertension and dyslipidemia are independent risk factors for cardiovascular mortality and are frequently present in the same patient. Fluvastatin (FV), used to reduce cholesterol levels, and lercanidipine (LER), used to ...

Abnormal matrix metalloproteinases (MMPs) activity causes cardiovascular diseases. Because hyperglycemia increase MMPs activities through increased oxidative stress. we hypothesized that antioxidant effects produced by ...

Increased expression/activity of matrix metalloproteinases (MMPs), especially MMP-2, plays a role in the vascular alterations induced by hypertension, and increased oxidative stress is a major factor activating MMPs. Here, ...

The vascular remodeling associated with hypertension involves oxidative stress and enhanced matrix metalloproteinases (MMPs) expression/activity, especially MMP-2. While previous work showed that lercanidipine, a ...